UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/593,247	07/02/2007	Foo Yew Liew	0380-P04195US00	7364
DANN, DORFMAN, HERRELL & SKILLMAN 1601 MARKET STREET SUITE 2400 PHILADELPHIA, PA 19103-2307			EXAMINER	
			MERTZ, PREMA MARIA	
			ART UNIT	PAPER NUMBER
			1646	
			MAIL DATE	DELIVERY MODE
			12/03/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)					
	10/593,247	LIEW ET AL.					
Office Action Summary	Examiner	Art Unit					
	Prema M. Mertz	1646					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 66(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	I.  nely filed  the mailing date of this communication.  D (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 16 Oc	ctober 2008.						
· <u> </u>	action is non-final.						
·=							
closed in accordance with the practice under E	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)⊠ Claim(s) <u>1-12,15 and 17-40</u> is/are pending in th	ne application.						
4a) Of the above claim(s) <u>1-11 and 18-31</u> is/are	4a) Of the above claim(s) <u>1-11 and 18-31</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.	· · · · · · · · · · · · · · · · · · ·						
7) Claim(s) is/are objected to.							
8) Claim(s) <u>12,15, 17, 32-40</u> are subject to restrict	tion and/or election requirement.						
Application Papers							
9)☐ The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11)☐ The oath or declaration is objected to by the Ex		` '					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign	priority under 35 LLS C & 119(a)	-(d) or (f)					
a) ☐ All b) ☐ Some * c) ☐ None of:	priority under 33 0.3.3. § 113(a)	-(a) or (i).					
1. Certified copies of the priority documents	s have been received						
2. Certified copies of the priority documents		on No					
<del>_</del>	3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of		d					
God the attached detailed emice deticition a list of	or the continue copies for reserve	u.					
Attachment(s)	4) There is a com-	(DTO 412)					
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)	4)						
3) Information Disclosure Statement(s) (PTO/SB/08)	5) 🔲 Notice of Informal P						
Paper No(s)/Mail Date	6)						

Application/Control Number: 10/593,247 Page 2

Art Unit: 1646

## **DETAILED ACTION**

1. Claims 13 and 14 have been canceled previously and claim 16 has been canceled in the

amendment filed 10/16/08. New claims 32-40 (10/16/08) have been added and are drawn to the

claimed invention.

Amended claim 12 is drawn to patentably distinct species of invention.

A species election on amended claims 12, 15, 17, and new claims 21-38 follows.

Election of species

2. This application contains claims directed to the following patentably distinct species of

disease of the claimed invention:

Applicants are required to elect one of the following species of disease selected from:

a) an autoimmune disease;

b) inflammatory disease;

c) prevention of allograft rejection; and

d) alleviation of allograft rejection.

If any one of autoimmune disease or inflammatory disease are elected, Applicants are

required to elect one of the sub-species of disease recited in claim 17 selected from:

arthritis, gastritis, pernicious anaemia, thyroiditis, insulitis, diabetes, sialoadenitis,

adrenalitis, orchitis/oophoritis, glomerulonephritis, experimental autoimmune encephalitis,

Page 3

multiple sclerosis, chronic obstructive pulmonary disease, atherosclerosis, and inflammatory bowel disease.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims12, 15, 21-38, are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

## Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (571) 272-0876. The examiner can normally be reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached on (571) 272-0835.

Official papers filed by fax should be directed to (571) 273-8300. Faxed draft or informal communications with the examiner should be directed to (571) 273-0876.

Information regarding the status of an application may be obtained from the Patent application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Prema Mertz/ Prema Mertz, Ph.D., J.D. Primary Examiner Art Unit 1646